BiotechTube

Olaratumab

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Stromal Tumor (GIST)

Conditions

Gastrointestinal Stromal Tumor (GIST)

Trial Timeline

Aug 1, 2011 → Nov 1, 2012

NCT ID
NCT01316263

About Olaratumab

Olaratumab is a phase 2 stage product being developed by Eli Lilly for Gastrointestinal Stromal Tumor (GIST). The current trial status is terminated. This product is registered under clinical trial identifier NCT01316263. Target conditions include Gastrointestinal Stromal Tumor (GIST).

What happened to similar drugs?

6 of 20 similar drugs in Gastrointestinal Stromal Tumor (GIST) were approved

Approved (6) Terminated (4) Active (10)
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
❌Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
🔄Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
🔄Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT03994627Pre-clinicalCompleted
NCT01316263Phase 2Terminated
NCT01199822Phase 1Completed

Competing Products

20 competing products in Gastrointestinal Stromal Tumor (GIST)

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
39
Patritumab deruxtecanDaiichi SankyoPhase 1/2
39
DS-6157aDaiichi SankyoPhase 1
21
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27
GemcitabineEli LillyPhase 1/2
32
pemetrexed + cisplatinEli LillyPhase 2
35
cetuximabEli LillyPhase 2
35
BBI503Sumitomo PharmaPhase 2
27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
35
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
32
FamitinibJiangsu Hengrui MedicinePhase 2
31
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
40
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
44
EsomeprazoleAstraZenecaPhase 3
40
AZD2171AstraZenecaPhase 2
35
EsomeprazoleAstraZenecaPhase 3
40